CoChat

Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity

Kaku, Kohei, Daida, Hiroyuki, Kashiwagi, Atsunori, Yamashina, Akira, Yamazaki, Tsutomu, Momomura, Shin-ichi, Iwase, Takashi, Yamasaki, Yoshimitsu, Nagatsuka, Kazuyuki, Kitagawa, Kazuo, Kawamori, Ryuzo · 2009 · Current Medical Research and Opinion
Cited by 27

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To evaluate the efficacy of pioglitazone for the prevention of macrovascular outcomes in Japanese patients with type 2 diabetes, without a recent history of macrovascular morbidity. RESEARCH DESIGN AND METHODS: This 2.5-4 year, prospective, randomized, open-label, blinded-endpoint study was conducted in 20 Japanese centers. Patients received pioglitazone +/- other oral glucose-lowering drugs (excluding another thiazolidinedione) [n = 293] or oral glucose-lowering drugs excluding thiazolidinediones (n = 294). Treatment was adjusted to achieve HbA(1c) < 6.5%. The primary endpoint was the time to onset of a macrovascular event. RESULTS: Pioglitazone delayed the time to onset of macrovascular events and was associated with a lower cumulative incidence of such events (3.56% vs. 4.49% for controls). Neither finding achieved statistical significance. This was likely because of the type of patient included in the study (i.e. no recent history of cardiovascular events) and the high use of concomitant anti-diabetic agents. Reductions in HbA(1c), fasting blood glucose and fasting blood insulin levels, and an increase in HDL-C were significantly greater with pioglitazone throughout most of the study (p < 0.05). Fewer patients in the pioglitazone group commenced permanent treatment with insulin (3.3% vs. 13.7% in the control group). Adverse events were reported by 97.6% of the pioglitazone group and 96.9% of the control group (serious adverse events, including deaths, were 20.1 vs. 22.2%, respectively). The only notable difference between the two groups was a higher incidence of edema in the pioglitazone group. The main limitation of this study was that too few patients were included to identify statistically significant differences in the primary endpoint. CONCLUSIONS: Pioglitazone produced good glycemic control in Japanese patients with type 2 diabetes, and significantly fewer patients treated with pioglitazone needed long-term insulin therapy. These changes were associated with a trend towards delayed onset of macrovascular events. CLINICAL TRIAL REGISTRATION: UMIN000001363.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1185/03007990903328124

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 13

  1. 10.2337/diacare.16.2.434 · DOI · Paper page
  2. 10.1136/bmj.322.7277.15 · DOI · Paper page
  3. 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
  4. 10.1016/S0140-6736(98)07037-8 · DOI · Paper page
  5. 10.1016/j.ahj.2005.09.015 · DOI · Paper page
  6. 10.7326/0003-4819-147-6-200709180-00178 · DOI · Paper page
  7. 10.1586/14779072.4.4.445 · DOI
  8. 10.1001/jama.299.13.1561 · DOI · Paper page
  9. 10.1016/S0140-6736(05)67528-9 · DOI · Paper page
  10. 10.1161/ATVBAHA.107.152835 · DOI
  11. 10.1161/01.STR.0000125864.01546.f2 · DOI · Paper page
  12. 10.2337/diacare.28.6.1463 · DOI · Paper page
  13. 10.1111/j.1368-5031.2004.0108.x · DOI

Cited by

Metadata

Authors
Kaku, K., Daida, H., Kashiwagi, A., Yamashina, A., Yamazaki, T., Momomura, S.-I., Iwase, T., Yamasaki, Y., Nagatsuka, K., Kitagawa, K., & Kawamori, R.
Venue
Current Medical Research and Opinion
Published
2009-10-16
Volume
25
Issue
12
Pages
2925-2932
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W2056867141
Cited by
27
References
3
FWCI
0.65
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.